Looking for an early success in PhII Alzheimer’s study, Biogen and Eisai just racked up the latest setback
Chalk up another big setback for the amyloid beta theory and another failed attempt at blazing a clinical path to success.
Investigators for Biogen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
